Health Friend Corporation: Subsidiary obtains US FDA approval for transfer registration of production site for Depo-Provera injection.

Jianyou Co., Ltd. announced that its subsidiary, Meitheal Pharmaceuticals, Inc., recently received approval from the U.S. Food and Drug Administration for the transfer of the production site of its Etoposide for Injection, 100mg/5mL, 500mg/25 mL and 1g/50mL, to be produced at the site of its subsidiary Jianjin Pharmaceutical Co., Ltd. The research and development expenses for Etoposide for Injection amounted to approximately 215.61 million RMB. The newly approved product will soon be launched in the U.S. market, which is expected to have a positive impact on the company's business performance.